Vol. 5 No. 12 (2025)
Reimbursement Reviews

Dupilumab (Dupixent)

decorative image of the issue cover

Published December 18, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses dupilumab (Dupixent), 300 mg single-use prefilled syringe or pen administered by subcutaneous injection.
  • Indication: As an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.